{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T15:15:04Z","timestamp":1783696504542,"version":"3.55.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.jtct.2025.01.887","type":"journal-article","created":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T12:20:55Z","timestamp":1737980455000},"page":"238.e1-238.e12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Utility of Thrombopoietin Receptor Agonists for Prolonged Thrombocytopenia After Chimeric Antigen Receptor T-cell Therapy"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2188-1719","authenticated-orcid":false,"given":"Donald","family":"Waddell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7435-3090","authenticated-orcid":false,"given":"Sarvnaz","family":"Sadrameli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jtct.2025.01.887_bib0001","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1182\/bloodadvances.2022008066","article-title":"Prolonged thrombocytopenia after CAR T-cell therapy: the role of thrombopoietin receptor agonists","volume":"7","author":"Drillet","year":"2023","journal-title":"Blood Adv"},{"issue":"10","key":"10.1016\/j.jtct.2025.01.887_bib0002","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1038\/s41409-019-0487-3","article-title":"Early and late hematologic toxicity following CD19 CAR-T cells","volume":"54","author":"Fried","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jtct.2025.01.887_bib0003","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.3390\/cancers14061501","article-title":"Cytopenia after CAR-T cell therapy\u2014a brief review of a complex problem","volume":"14","author":"Sharma","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"24","key":"10.1016\/j.jtct.2025.01.887_bib0004","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1182\/blood.2020010543","article-title":"CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed\/refractory large B-cell lymphoma","volume":"138","author":"Rejeski","year":"2021","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jtct.2025.01.887_bib0005","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJMct1014202","article-title":"Thrombopoietin-receptor agonists for primary immune thrombocytopenia","volume":"365","author":"Imbach","year":"2011","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.jtct.2025.01.887_bib0006","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s40265-021-01553-7","article-title":"Thrombopoietin receptor agonists (TPO-RAs): drug class considerations for pharmacists","volume":"81","author":"Gilreath","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.jtct.2025.01.887_bib0007","series-title":"Promacta [Package Insert]","year":"2021"},{"key":"10.1016\/j.jtct.2025.01.887_bib0008","series-title":"Nplate [Package Insert]","year":"2021"},{"issue":"10","key":"10.1016\/j.jtct.2025.01.887_bib0009","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1185\/03007995.2010.510051","article-title":"A randomized, double-blind, placebo-controlled, dose ranging study to assess the efficacy and safety of eltrombopag in patients receiving carboplatin\/paclitaxel for advanced solid tumors","volume":"26","author":"Kellum","year":"2010","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"10.1016\/j.jtct.2025.01.887_bib0010","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/cam4.326","article-title":"Eltrombopag with gemcitabine-based chemotherapy in patients with advanced solid tumors: a randomized phase I study","volume":"4","author":"Winer","year":"2015","journal-title":"Cancer Med"},{"issue":"31","key":"10.1016\/j.jtct.2025.01.887_bib0011","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1200\/JCO.18.01931","article-title":"Romiplostim treatment of chemotherapy-induced thrombocytopenia","volume":"37","author":"Soff","year":"2019","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.jtct.2025.01.887_bib0012","first-page":"1217","article-title":"Romiplostim for management of chemotherapy-induced thrombocytopenia","volume":"22","author":"Parameswaran","year":"2014","journal-title":"Support Care Cancer"},{"issue":"4","key":"10.1016\/j.jtct.2025.01.887_bib0013","doi-asserted-by":"crossref","first-page":"e169","DOI":"10.3324\/haematol.2017.180166","article-title":"The use of romiplostim in treating chemotherapy-induced thrombocytopenia in patients with solid tumors","volume":"103","author":"Al-Samkari","year":"2018","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.jtct.2025.01.887_bib0014","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood.2023020578","article-title":"Immune effector cell-associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations","volume":"142","author":"Rejeski","year":"2023","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jtct.2025.01.887_bib0015","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.3324\/haematol.2018.212845","article-title":"Thrombopoietin receptor agonists: ten years later","volume":"104","author":"Ghanima","year":"2019","journal-title":"Haematologica"},{"issue":"13","key":"10.1016\/j.jtct.2025.01.887_bib0016","first-page":"1171","article-title":"Eltrombopag for the treatment of chronic immune (idiopathic) thrombocytopenic purpura","volume":"23","author":"Dmytrijuk","year":"2009","journal-title":"Oncology (Williston Park)"},{"issue":"4","key":"10.1016\/j.jtct.2025.01.887_bib0017","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/ejh.14141","article-title":"Safety and efficacy of eltrombopag in patients with post-CAR T cytopenias","volume":"112","author":"Wesson","year":"2024","journal-title":"Eur J Haematol"},{"issue":"2","key":"10.1016\/j.jtct.2025.01.887_bib0018","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1093\/annonc\/mdp297","article-title":"The frequency, manifestations, and duration of prolonged cytopenias after first-line fludarabine combination chemotherapy","volume":"21","author":"Gill","year":"2010","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.jtct.2025.01.887_bib0019","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002721","article-title":"Thrombopoietin receptor agonists for acquired thrombocytopenia following anti-CD19 CAR-T-cell therapy: a case report","volume":"9","author":"Baur","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"12","key":"10.1016\/j.jtct.2025.01.887_bib0020","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1002\/ajh.25275","article-title":"Thrombopoietin level predicts response to treatment with eltrombopag and romiplostim in immune thrombocytopenia","volume":"93","author":"Al-Samkari","year":"2018","journal-title":"Am J Hematol"},{"issue":"16","key":"10.1016\/j.jtct.2025.01.887_bib0021","doi-asserted-by":"crossref","first-page":"4719","DOI":"10.1182\/bloodadvances.2022007776","article-title":"Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy","volume":"6","author":"Rejeski","year":"2022","journal-title":"Blood Adv"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725009157?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725009157?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:52:06Z","timestamp":1775004726000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636725009157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S2666636725009157"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2025.01.887","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Utility of Thrombopoietin Receptor Agonists for Prolonged Thrombocytopenia After Chimeric Antigen Receptor T-cell Therapy","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2025.01.887","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}